Literature DB >> 17657222

The multi-functional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation.

L F Peterson1, Y Wang, M-C Lo, M Yan, E Kanbe, D-E Zhang.   

Abstract

The 8;21 translocation is a common chromosomal abnormality in acute myeloid leukemia (AML). We recently identified a naturally occurring leukemogenic splice variant, AML1-ETO9a (acute myeloid leukemia-1 transcription factor and the eight-twenty-one corepressor-9a), of t(8;21). To understand the leukemic potential of AML1-ETO9a, we performed microarray analysis with the murine multipotential hematopoietic FDCP-mix A4 cell line. We identified changes in expression of various genes including CD44. CD44 is a type I transmembrane protein and functions as the major cellular adhesion molecule for hyaluronic acid, a component of the extracellular matrix. CD44 is expressed in most human cell types and is implicated in myeloid leukemia pathogenesis. We show that the presence of AML1-ETO9a significantly increased the expression of CD44 at both RNA and protein levels. Furthermore, the CD44 promoter is bound by AML1-ETO9a and AML1-ETO at the chromatin level. In addition, in the AML1-ETO9a leukemia mouse model CD44 is regulated in a cell context-dependent manner. Thus, our observations suggest that AML1-ETO and its splice variant AML1-ETO9a are able to regulate the expression of the CD44 gene, linking the 8;21 translocation to the regulation of a cell adhesion molecule that is involved in the growth and maintenance of the AML blast/stem cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17657222     DOI: 10.1038/sj.leu.2404849

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  18 in total

1.  Variable selection for discriminant analysis with Markov random field priors for the analysis of microarray data.

Authors:  Francesco C Stingo; Marina Vannucci
Journal:  Bioinformatics       Date:  2010-12-14       Impact factor: 6.937

2.  The truncated RUNX1/ETO activates VLA-4-dependent adhesion and migration of hematopoietic progenitor cells.

Authors:  Kanagaraju Ponnusamy; Linping Chen-Wichmann; Olga N Kuvardina; Jörn Lausen; Reinhard Henschler; Christian Wichmann
Journal:  Haematologica       Date:  2014-08-08       Impact factor: 9.941

3.  Combined gene expression and DNA occupancy profiling identifies potential therapeutic targets of t(8;21) AML.

Authors:  Miao-Chia Lo; Luke F Peterson; Ming Yan; Xiuli Cong; Fulai Jin; Wei-Jong Shia; Shinobu Matsuura; Eun-Young Ahn; Yukiko Komeno; Minh Ly; Hans B Ommen; I-Ming Chen; Peter Hokland; Cheryl L Willman; Bing Ren; Dong-Er Zhang
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

4.  Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.

Authors:  John Anto Pulikkan; Dmitri Madera; Liting Xue; Paul Bradley; Sean Francis Landrette; Ya-Huei Kuo; Saman Abbas; Lihua Julie Zhu; Peter Valk; Lucio Hernán Castilla
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

5.  CD44 ligation with A3D8 antibody induces apoptosis in acute myeloid leukemia cells through binding to CD44s and clustering lipid rafts.

Authors:  Hao Qian; Lijuan Xia; Peixue Ling; Samuel Waxman; Yongkui Jing
Journal:  Cancer Biol Ther       Date:  2012-08-16       Impact factor: 4.742

6.  Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR.

Authors:  Fangyang Wang; Damián Gatica; Zhang Xiao Ying; Luke F Peterson; Peter Kim; Denzil Bernard; Kamlai Saiya-Cork; Shaomeng Wang; Mark S Kaminski; Alfred E Chang; Tycel Phillips; Daniel J Klionsky; Sami N Malek
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

7.  RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.

Authors:  Russell C DeKelver; Benjamin Lewin; Stephanie Weng; Ming Yan; Joseph Biggs; Dong-Er Zhang
Journal:  Leuk Lymphoma       Date:  2013-07-25

8.  Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.

Authors:  Zhang Xiao Ying; Meiyan Jin; Luke F Peterson; Denzil Bernard; Kamlai Saiya-Cork; Mehmet Yildiz; Shaomeng Wang; Mark S Kaminski; Alfred E Chang; Daniel J Klionsky; Sami N Malek
Journal:  Clin Cancer Res       Date:  2016-06-07       Impact factor: 12.531

9.  t(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression.

Authors:  Akiko J Okumura; Luke F Peterson; Fumihiko Okumura; Anita Boyapati; Dong-Er Zhang
Journal:  Blood       Date:  2008-05-29       Impact factor: 22.113

10.  Applications of microarray technology to Acute Myelogenous Leukemia.

Authors:  Rashmi S Goswami; Mahadeo A Sukhai; Mariam Thomas; Patricia P Reis; Suzanne Kamel-Reid
Journal:  Cancer Inform       Date:  2008-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.